OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO(TM) in Refractory Metastatic Melanoma

Classification as an ATMP Positions TAVO for Accelerated Review and Approval in Europe SAN DIEGO and PENNINGTON, N.J., April 1, 2019 -- (Healthcare Sales & Marketing Network) -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developin... Biopharmaceuticals, Oncology, Regulatory OncoSec Medical, TAVO , metastatic melanoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news